Opportunities for growth as well as favorable regulatory measures within the pharmaceutical market in Latin America are making
the region more attractive than ever. According to IMS Health, the entire Latin-American region is expected to grow to $51.3
billion by 2014.
Photo: Joseph Sohm-Visions of America / Getty
"Latin America's pharma market in general has shown a growth trend similar to Asian markets in terms of sales, around 12%
to 16%," says Carlos Kiffer, operations director for GC2, a pharmaceutical R&D company based in São Paulo, Brazil.
Demand for pharmaceuticals and other products is increasing across the region, despite the global credit crisis, according
to the Economic Commission for Latin America and the Caribbean (ECLAC), a United Nations organization with headquarters in
Santiago, Chile. As a result, Latin American countries are expected to grow in total approximately 4.7% this year, projects
ECLAC. In 2010, the region grew 5.9%.
This economic performance is attracting global attention. Trade and manufacturing practice are also playing a role in the
region's success. For example, the seven largest Latin American countries—Brazil, Mexico, Venezuela, Argentina, Colombia,
Chile, and Peru—have all become signatories to international trade treaties such as the Trade-Related aspects of Intellectual
Property Rights (TRIPS) treaty. Brazil and Mexico have been applying GMPs in their pharmaceutical industries for years. These
practices are positive factors for investors, according to Carlos Kiffer, who also works as a researcher for the Federal University
of São Paulo.
Brazil increases healthcare access
Brazil, in particular, has the largest pharmaceutical market in Latin America and "leads in terms of gross sales with an average
of $12 billion per year," according to Kiffer. The country's R&D market represents approximately 5% of total gross sales,
This year looks good so far. IMS Health projects the pharmaceutical industry in Brazil alone will grow approximately 10% and
report total revenues of $25.6 billion in 2011. By the year 2015, the market is projected to reach $32.8 billion, according
to Business Monitor International (BMI).
Brazil's potential lies in its population of nearly 200 million inhabitants, many of whom are just gaining access to private
healthcare and generic drugs. During the past decade, the government has put controls into place to end sky-rocketing inflation,
consolidated its economy, and opened the door to goods and services for millions of Brazilians, many of whom had been living
in poverty. As a result of the changes, private healthcare firms based in the southeast of Brazil—the most developed region
of the country—have reported double-digit growth in profits in the past few years.
Government measures regarding fiscal adjustments have increased Brazil's competitive edge and boosted investments from the
private sector as well. According to BMI, imports of goods produced outside South America, including pharmaceuticals, are
expected to drop due to legislation passed in 2010 (Law number 12.349/2010). The new law gives preference to goods and services
provided by domestic or foreign companies installed within the Mercosur economic bloc. Mercosur, also known as the Southern
Common Market, is made up of Argentina, Brazil, Paraguay, and Uruguay. Bolivia, Chile, Colombia, Ecuador, and Peru have associate-member
status in the bloc.
"We therefore expect growth in the generic-drug sector to outpace the rest of the industry, especially in terms of sales volume,"
according to a February 2011 BMI report titled, Industry Trend Analysis.
Generic-drug sales in Brazil represented 17.2% of the pharmacy sector by value and 21.3% by volume in 2010. The sector is
expected to increase to around 25% by 2015, according to industry data.
Market consolidation is underway as well. Recent acquisitions of domestic firms by giant multinationals have changed the local
market considerably. And despite growing market share by foreign investors, growth and opportunities for smaller biotech firms
are still expected, primarily because of the country's rich biodiversity, according to Brazil's National Pharmaceutical Laboratories